Multi-omics analyses revealed that TGF-β-driven fibrosis creates pro-tumor niches, and targeting this pathway alongside CSF-1R inhibition improved survival in preclinical models (Watson et al., 2024). This evidence concerns the gene TGFB1 and neoplasm.